Larimar Therapeutics, Inc. Cash Flow Statement
LRMR|6 years of annual SEC 10-K data (FY2014-FY2019)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Larimar Therapeutics, Inc. used $44M in operating cash flow and negative free cash flow of $44M in FY2019.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|
| Net Income | -$52.0M | -$57.9M | -$74.3M | -$36.5M | -$14.0M | -$13.9M |
| Depreciation & Amortization | $188.0K | $212.0K | $70.0K | $16.0K | $12.0K | $11.0K |
| Operating Cash Flow | -$43.8M | -$52.0M | -$59.6M | -$28.2M | -$15.0M | -$13.6M |
| Capital Expenditures | $55.0K | $660.0K | $595.0K | $58.0K | $17.0K | $2.0K |
| Free Cash Flow | -$43.8M | -$52.6M | -$60.1M | -$28.3M | -$15.0M | -$13.6M |